SequelSEC

PHIBRO ANIMAL HEALTH CORP PAHC

Pharmaceutical Preparations · CIK 0001069899 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
$396.75M
Fiscal year ended 2026-06-30
Operating income
$48.16M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

PHIBRO ANIMAL HEALTH CORP (PAHC) reported revenue of $396.75M and net income of $21.71M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PHIBRO ANIMAL HEALTH CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

PHIBRO ANIMAL HEALTH CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$396.75M$383.54M$373.91M$363.89M$378.70M$347.82M$309.26M$260.43M$273.16M$263.22M
Cost of revenue$262.35M$257.87M$241.25M$244.11M$268.69M$243.26M$207.39M$176.94M$186.01M$183.62M
Gross profit$134.40M$125.68M$132.66M$119.78M$110.01M$104.57M$101.87M$83.50M$87.15M$79.60M
Operating income$48.16M$44.65M$50.33M$51.26M$33.72M$33.52M$25.53M$17.70M$18.42M$19.92M
Net income$21.71M$24.02M$27.46M$26.53M$17.22M$20.88M$3.18M$6.98M$752.00K$8.40M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableshares 41.04Mshares 40.96Mshares 40.88MUnavailableshares 40.71Mshares 40.72Mshares 40.58MUnavailableshares 40.52M
Pretax income$32.34M$32.31M$36.42M$36.27M$23.85M$29.69M$4.84M$9.62M$6.41M$12.92M
Income tax expense$10.63M$8.29M$8.97M$9.74M$6.62M$8.81M$1.65M$2.64M$5.66M$4.52M
Diluted EPSUnavailable$0.59$0.67$0.65Unavailable$0.51$0.08$0.17Unavailable$0.21
Selling, general & administrative$86.24M$81.02M$82.33M$68.52M$76.29M$71.05M$76.34M$65.80M$68.73M$59.68M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PHIBRO ANIMAL HEALTH CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$61.42M$54.93M$55.49M$72.77M$68.04M$60.35M$67.07M$51.84M$70.61M$50.22M
Total assets$1.50B$1.45B$1.41B$1.39B$1.36B$1.32B$1.29B$966.29M$982.18M$979.04M
Current assets$935.51M$894.07M$862.18M$835.80M$810.61M$776.02M$746.15M$570.77M$601.00M$597.18M
Total liabilities$1.12B$1.08B$1.07B$1.07B$1.08B$1.05B$1.04B$707.76M$725.54M$708.94M
Current liabilities$316.47M$281.87M$282.37M$270.14M$293.47M$266.48M$233.25M$176.89M$204.15M$189.07M
Total equity incl. NCI$385.48M$361.83M$332.36M$311.68M$285.68M$265.99M$246.80M$258.53M$256.64M$270.09M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$534.88M$539.70M$517.35M$471.78M$444.42M$448.39M$427.22M$272.56M$265.91M$282.29M
Accounts receivable$238.79M$221.55M$215.87M$217.90M$227.98M$197.52M$191.79M$160.78M$169.45M$161.09M
Goodwill$60.04M$59.89M$59.81M$59.71M$59.64M$54.57M$54.55M$54.59M$54.56M$54.64M
Long-term debtUnavailable$597.68M$603.60M$609.52M$615.44M$619.16M$622.88M$287.67M$282.29M$291.01M
Accounts payable$127.31M$129.64M$133.30M$130.60M$138.20M$131.62M$99.44M$86.53M$85.57M$82.61M

Cash flow

PHIBRO ANIMAL HEALTH CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$24.09M$16.21M$19.35M$9.30M$21.27M$43.15M$3.08M$12.62M$28.43M$11.41M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$16.45M-$16.81M-$17.18M-$21.01M-$7.03M-$18.25M-$260.47M-$2.93M-$9.11M$1.13M
Financing cash flow-$1.62M-$2.30M-$18.98M$16.34M-$7.77M-$32.22M$276.32M-$29.20M$1.79M$4.85M
Net change in cash$6.49M-$557.00K-$17.28M$4.73M$7.68M-$6.72M$15.24M-$18.78M$20.39M$17.26M
Stock-based compensation$413.00K$411.00K$434.00K$339.00K$179.00K$179.00K$180.00K$179.00K$179.00K$135.00K
Common dividends paid$4.87M$4.87M$4.86M$4.86M$4.86M$4.86M$4.86M$4.86M$4.86M$4.86M
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$13.34M$12.45M$12.89M$12.83M$12.41M$12.62M$11.57M$9.00M$9.20M$9.20M

Derived

PHIBRO ANIMAL HEALTH CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin33.9%32.8%35.5%32.9%29.0%30.1%32.9%32.1%31.9%30.2%
Operating margin12.1%11.6%13.5%14.1%8.9%9.6%8.3%6.8%6.7%7.6%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue0.1%0.1%0.1%0.1%0.0%0.1%0.1%0.1%0.1%0.1%
Current ratio2.96x3.17x3.05x3.09x2.76x2.91x3.20x3.23x2.94x3.16x
Revenue YoY growth4.8%10.3%20.9%39.7%38.6%32.1%23.7%12.6%7.1%7.1%
Net margin5.5%6.3%7.3%7.3%4.5%6.0%1.0%2.7%0.3%3.2%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailable1.65xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate32.9%25.7%24.6%26.9%27.8%29.7%34.2%27.5%88.3%35.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PAHC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-08-26View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-Q · Filed 2026-02-04View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-K · Filed 2025-08-27View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.